ArticleJAMA network open2026
Tumor Vascular Features and Colorectal Cancer-Specific Mortality.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The phenotypic and morphologic heterogeneity of tumor vasculature in colorectal cancer (CRC) has been increasingly recognized; however, its clinical importance remains unclear. Objective: To examine whether specific tumor vascular features are associated with CRC-specific mortality. Design, Setting, and Participants: The prospective cohort incident-tumor biobank method (PCIBM) was used to analyze data from the Nurses' Health Study and the Health Professionals Follow-up Study, in which 4476 incident CRC cases were documented and resected tumor tissue specimens were collected. Immunofluorescence staining was conducted from July 30 to August 14, 2024, and data analyses were performed between December 2024 and June 2025. Exposures: Tumor vascular features were assessed by in situ multispectral immunofluorescence. The study used an in situ multispectral immunofluorescence assay targeting ACKR1 (atypical chemokine receptor 1), CD34 (cluster of differentiation 34), CD36 (cluster of differentiation 36), KDR (kinase insert domain receptor), LAMB1 (laminin subunit β1), MADCAM1 (mucosal addressin cell adhesion molecule 1), and KRT (keratin) combined with machine learning to characterize tumor vasculature. The vessels were morphologically classified as micro, collapsed, patent, and irregular. Multivariable-adjusted Cox proportional hazards regression models were used to assess CRC mortality. Main Outcomes and Measures: CRC-specific mortality assessed using multivariable adjusted Cox proportional hazards regression models. Results: Tumor vessels were successfully analyzed in 837 patients with CRC (median [IQR] age at diagnosis, 69 [63-75] years; 466 [56%] female). During a median (IQR) follow-up of 11.8 (8.7-14.7) years for censored cases, there were 628 all-cause deaths, including 263 CRC-specific deaths. Multivariable-adjusted CRC-specific mortality hazard ratios were 0.39 (95% CI, 0.25-0.60; P for trend <.001) for overall CD34+ vessel density in quartile 4 (vs quartile 1), 0.48 (95% CI, 0.31-0.74; P for trend = .004) for micro CD34+ vessel proportion in quartile 4, 1.58 (95% CI, 1.07-2.32; P for trend = .004) for CD34+CD36+ vessel proportion highest category (vs lowest category), and 1.78 (95% CI, 1.22-2.61; P for trend <.001) for CD34+LAMB1+ vessel proportion highest category. Conclusions and Relevance: In this PCIBM-based study of patients with CRC, higher overall CD34+ vessel density was associated with better prognosis, whereas higher CD34+CD36+ and CD34+LAMB1+ vessel proportions were associated with worse prognosis. These findings suggest that tumor vasculature may have a role as a prognostic biomarker and potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.